STRIDES PHARMA SCIENCE LIMITED
₹1,069.15-₹28.25 (-2.6%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹8,552 Cr
- P/E
- 112.0x
- EV / EBITDA
- 35.5x
- Revenue
- ₹2,139 Cr
- Net margin
- 2.4%
- ROCE
- 2.9%
Price chart
Technical chartScreen technicals →+25.8% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -4.4%
- 3M
- -0.4%
- 6M
- +3.2%
- 1Y
- +25.8%
- 5Y
- +98.0%
52-week range
Day change -₹28.25 (-2.6%) from ₹1,097 to ₹1,069 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in STAR, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Maintains healthy dividend payout of 52.0%
Concerns1
- Low interest coverage ratio of 1.1x
Rule-based from financial data. Not advice.
About the company
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams.
Read moreShow less
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. The company was incorporated in 1990 and is based in Bengaluru, India.
- Sector
- Healthcare
- Shares outstanding
- 9.2 Cr shares
- ISIN
- INE939A01011
- BSE code
- 532531
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹8,552 Cr
- P/E
- 112.0x
- P/B
- 2.7x
- EV / EBITDA
- 35.5x
- EV / Sales
- 5.2x
- P/S
- 4.6x
- Earnings yield
- 0.9%
- 52-week high
- ₹1,236.90
- 52-week low
- ₹793.60
Profitability
- Operating margin
- 8.1%
- Net margin
- 2.4%
- EBITDA margin
- 14.6%
- ROE
- 1.3%
- ROCE
- 2.9%
- ROA
- 0.8%
- Dividend payout
- 52.0%
- Tax rate
- 3.0%
- Other income, % of PBT
- 265.2%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹2,139 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 14.6%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 2.0%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹273 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 62.5%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 6313.3%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -17.8%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹14.0 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -105.8%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹86.0 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 5.0%
Solvency and efficiency
- Current ratio
- 7.35
- Debt / Equity
- 0.48
- Debt / Assets
- 0.29
- Debt / EBITDA
- 6.18
- Interest coverage
- 1.09
- Financial leverage
- 1.67
- CFO / Net profit
- -0.31
- Cash / Market cap
- 31.4%
- Cash per share
- ₹290.62
- Asset turnover
- 0.32
- Fixed asset turnover
- 2.50
- Capital intensity
- 0.40
- Debtor days
- 306 days
- Inventory turnover
- 1.94
- Cash conversion cycle
- 289 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹135 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹1,876 Cr |
| Sales | Operating profit | ₹263 Cr |
| Operating profit | Interest | ₹146 Cr |
| Operating profit | Depreciation | ₹85 Cr |
| Operating profit | Profit before tax | ₹32 Cr |
| Other income | Profit before tax | ₹2,873 Cr |
| Profit before tax | Tax and other | ₹19 Cr |
| Profit before tax | Net profit | ₹2,886 Cr |
Revenue and net profit
Revenue grew 14.6% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹1,858 Cr | ₹78 Cr |
| FY2022 | ₹1,979 Cr | ₹180 Cr |
| FY2023 | ₹1,854 Cr | ₹5 Cr |
| FY2024 | ₹1,866 Cr | ₹45 Cr |
| FY2025 | ₹2,139 Cr | ₹2,886 Cr |
Cash flows
FY2025: ₹421 Cr from operations, ₹283 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹283 Cr | ₹7 Cr |
| FY2022 | -₹283 Cr | -₹264 Cr |
| FY2023 | ₹242 Cr | ₹59 Cr |
| FY2024 | -₹14 Cr | -₹83 Cr |
| FY2025 | ₹421 Cr | ₹283 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹2,139 Cr+14.6%1Y
- Net profit
- ₹2,886 Cr+6,313.3%1Y
- Cash from operations
- ₹421 Cr
- Free cash flow
- ₹283 Cr
- Revenue CAGR, 5Y
- 2.0%
- EBITDA CAGR, 5Y
- -1.7%
- Net profit CAGR, 5Y
- -17.8%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹2,139 Cr | ₹263 Cr | — | ₹2,886 Cr | ₹421 Cr | ₹283 Cr | 90.4% | +14.6% | +6313.3% |
Monthly returns
Month-by-month returns of STAR across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹5,031 Cr |
| Equity capital | ₹92 Cr |
| Reserves | ₹3,101 Cr |
| Borrowings | ₹1,202 Cr |
| Other liabilities | ₹636 Cr |
| Assets | ₹5,031 Cr |
| Fixed assets | ₹767 Cr |
| Capital work in progress | ₹106 Cr |
| Investments | ₹1,848 Cr |
| Other assets | ₹2,311 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
STAR trades at 112.0x earnings against a peer median of 52.6x (a 113% premium).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| STRIDES PHARMA SCIENCE LIMITEDSTARthis companyP/E ↑ premium | ₹8,552 Cr | 112.0x | 2.7x | 1.3% | 35.5x |
| Sanofi India LtdSANOFI | ₹9,387 Cr | 25.4x | 12.0x | — | — |
| Jeena Sikho Lifecare LimitedJSLL | ₹8,968 Cr | 58.2x | 25.2x | 35.9% | 90.3x |
| PROCTER & GAMBLE HEALTH LIMITEDPGHL | ₹8,946 Cr | 29.2x | 14.4x | — | — |
| Jupiter Life Line Hospitals LimitedJLHL | ₹8,877 Cr | 46.3x | 5.9x | 12.2% | 34.5x |
| Corona Remedies LimitedCORONA | ₹8,749 Cr | 55.1x | — | 18.8% | 55.0x |
| Blue Jet Healthcare LimitedBLUEJET | ₹8,659 Cr | 24.6x | 6.9x | 19.4% | 34.4x |
| Sequent Scientific LimitedVIYASH | ₹8,288 Cr | 531.0x | 4.1x | 0.1% | 633.5x |
| Marksans Pharma Ltd.MARKSANS | ₹7,873 Cr | 32.7x | 5.3x | 11.0% | 38.1x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
STAR since 1 January, against earlier years.
Historical volatility
STAR's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 9.0% |
| FY2022 | 4.0% |
| FY2023 | 5.0% |
| FY2024 | 8.0% |
| FY2025 | 12.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹2,139 Cr |
| Costs | |
| Interest | ₹146 Cr |
| Expenses | ₹1,877 Cr |
| Operating profitOperating Profit | ₹263 Cr |
| Other income and charges | |
| Profit before tax | ₹2,905 Cr |
| Tax | |
| Net profitNet Profit | ₹2,886 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹5,031 Cr |
| Equity capitalEquity Capital | ₹92 Cr |
| Reserves | ₹3,101 Cr |
| Borrowings | ₹1,202 Cr |
| Other liabilitiesOther Liabilities | ₹636 Cr |
| AssetsTotal Assets | ₹5,031 Cr |
| Fixed assetsFixed Assets | ₹767 Cr |
| Capital work in progressCWIP | ₹106 Cr |
| Investments | ₹1,848 Cr |
| Other assetsOther Assets | ₹2,311 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹421 Cr |
| Investing cash flowCash from Investing Activity | -₹138 Cr |
| Financing cash flowCash from Financing Activity | -₹370 Cr |
| Change in cashNet Cash Flow | -₹86 Cr |
Learn while you research
Academy chapters picked for STRIDES PHARMA SCIENCE LIMITED and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 112.0, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read